Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
NCT04633187 is registered in ClinicalTrials.gov with Enanta Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 7, 2021
- Completion date
- May 31, 2023
- Enrollment
- 9 (actual)
- Sites
- 64
Conditions
As the registry lists them; a condition with its own page is linked.